|
Market Closed -
NYSE
05:00:02 11/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 89.01 USD | +4.41% |
|
-2.63% | +12.16% |
| 11-10 | Argus Research Adjusts CVS Health Price Target to $105 From $114 | MT |
| 11-07 | CVS Health Insider Bought Shares Worth $2,001,315, According to a Recent SEC Filing | MT |
| Market Cap | 114B 102B 94.13B 85.48B 162B 10,678B 166B 1,127B 449B 5,721B 427B 418B 18,085B | P/E 2026 * |
12.6x | P/E 2027 * | 12.2x |
|---|---|---|---|---|---|
| Enterprise Value | 167B 150B 138B 126B 238B 15,683B 244B 1,655B 660B 8,402B 628B 614B 26,562B | EV / Sales 2026 * |
0.4x | EV / Sales 2027 * | 0.38x |
| Free-Float |
71.21% | Yield 2026 * |
3% | Yield 2027 * | 3.06% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CVS | Delayed | |
CBOE
| CVS | Real-time | |
|
Tradegate
| CVS | Real-time | |
|
Xetra
| CVS | Delayed | |
|
Mexican S.E.
| CVS * | End-of-day quote | |
|
Boerse Muenchen
| CVS | Real-time | |
|
Börse Stuttgart
| CVS | Delayed | |
|
London S.E.
| 0HRS | Delayed | |
|
Deutsche Boerse AG
| CVS | Delayed | |
|
Wiener Boerse
| CVS | End-of-day quote | |
|
Santiago S.E.
| CVS | End-of-day quote | |
|
Lima
| CVSUS | End-of-day quote | |
|
Borsa Italiana
| 1CVS | End-of-day quote | |
|
Santiago S.E.
| CVSCL | End-of-day quote | |
|
CBOE
| 0HRS | Real-time | |
|
CBOE
| Real-time | ||
|
Swiss Exchange
| CVS | Delayed | |
|
Swiss Exchange
| CVS | Delayed |
Last Transcript: CVS Health Corporation
| 1 day | +4.41% | ||
| 1 week | -2.63% | ||
| Current month | -1.37% | ||
| 1 month | +3.31% | ||
| 3 months | -6.96% | ||
| 6 months | -1.70% | ||
| Current year | +12.16% |
| 1 week | 79.66 |  | 89.08 |
| 1 month | 77.33 | | 95.26 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 17/10/2024 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 12/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 01/03/2007 |
Anne Finucane
BRD | Director/Board Member | 73 | 20/01/2011 |
| Director/Board Member | 71 | 05/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/11/26 | Buy | Executive/Senior Manager | 23,855 | 0.0019% | ||
| 31/5/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 31/5/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.41% | -2.63% | +14.79% | +31.52% | 114B | |
| -0.09% | +8.98% | +9.82% | +116.66% | 105B | |
| -2.62% | -19.72% | +50.98% | +567.48% | 45.24B | |
| +1.93% | +9.55% | +11.61% | +113.54% | 33.58B | |
| -0.26% | +4.79% | +42.03% | +81.11% | 30.12B | |
| -0.47% | +4.61% | +40.22% | +94.58% | 28.43B | |
| +0.44% | +8.84% | +49.10% | +439.64% | 23.1B | |
| +0.23% | +2.73% | -17.74% | -15.87% | 20.02B | |
| -0.65% | -1.16% | -7.35% | +30.12% | 16.86B | |
| +4.83% | +3.79% | +115.94% | - | 15.1B | |
| Average | +0.78% | +1.52% | +30.94% | +162.09% | 43B | |
| Weighted average by Cap. | +1.15% | +1.11% | +23.70% | +146.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 421B 378B 348B 316B 598B 39,486B 615B 4,168B 1,661B 21,155B 1,581B 1,547B 66,878B | 431B 386B 356B 323B 612B 40,373B 629B 4,261B 1,698B 21,631B 1,616B 1,582B 68,380B |
| Net income | 9.04B 8.1B 7.47B 6.78B 12.84B 847B 13.19B 89.42B 35.63B 454B 33.91B 33.19B 1,435B | 9.31B 8.35B 7.7B 6.99B 13.23B 873B 13.6B 92.15B 36.72B 468B 34.95B 34.21B 1,479B |
| Net Debt | 53.38B 47.87B 44.12B 40.07B 75.83B 5,005B 77.95B 528B 210B 2,682B 200B 196B 8,477B | 48.65B 43.63B 40.21B 36.52B 69.11B 4,561B 71.04B 481B 192B 2,444B 183B 179B 7,726B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/11/26 | US$89.01 | +4.41% | 15,116,051 |
| 09/11/26 | US$85.25 | +1.67% | 11,253,761 |
| 06/11/26 | US$83.85 | +3.10% | 16,099,672 |
| 05/11/26 | US$81.33 | +1.71% | 19,930,575 |
| 04/11/26 | US$79.96 | -12.53% | 34,289,772 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
